Targeted Cancer Therapy Connect is a peer-reviewed, open-access journal dedicated to advancing precision and targeted approaches in cancer treatment. The journal publishes innovative research that deepens understanding of the molecular and immunological mechanisms driving cancer progression and therapeutic response. Our goal is to accelerate the translation of scientific discoveries into effective, patient-centered cancer therapies.
The journal’s scope covers the following areas:
- Molecular Targets and Mechanisms – Discovery and validation of therapeutic targets; roles of oncogenes, tumor suppressors, signaling pathways, and the tumor microenvironment.
- Targeted Therapeutics – Development of small-molecule inhibitors, monoclonal antibodies, antibody–drug conjugates (ADCs), peptide- and protein-based drugs, and next-generation modalities such as PROTACs.
- Immunotherapy and Precision Oncology – Immune checkpoint inhibitors, bispecific antibodies, CAR-T and TCR-based therapies, vaccines, and biomarker-guided treatment strategies.
- Drug Resistance and Combination Therapy – Mechanisms of resistance and rational combination regimens integrating targeted and immune-based agents.
- Clinical Translation – Clinical trials of targeted agents, pharmacogenomics, predictive biomarkers, and case reports highlighting successful targeted interventions.
- Technological and Methodological Advances – CRISPR, single-cell omics, proteomics, nanomedicine, and computational or AI-driven approaches for target discovery and drug development.
Targeted Cancer Therapy Connect aims to serve as a platform for researchers, clinicians, and industry experts to share insights, foster collaboration, and explore emerging directions in targeted and immune-based cancer treatment.
